“…97,98,[105][106][107][108][109][110] Ceftizoxime alapivoxil (AS-924) 2, which is a prodrug of the second generation cephalosporin ceftizoxime, is in preregistration in Japan and was developed by Kyoto Yakuhin and licensed to Asahi Kasei Pharma. 109,111,112 Basilea Pharmaceutica is developing the cephalosporin ceftobiprole (BAL-5788, Ro-65-5788) 3, a prodrug of BAL-9141 (Ro-63-9141), as a broad spectrum antibiotic with activity against both Gram positive and negative bacteria. Faropenem daloxate (SUN-208, BAY-56-6824) 6 is an orally active, penem-type b-lactam that was licensed to Replidyne by Daiichi Suntory Pharma in August 2004.…”